#United States #San Diego #CFO #Halozyme #David Ramsay

Halozyme Therapeutics Welcomes David Ramsay as Interim Chief Financial Officer

Halozyme Therapeutics, Inc., a prominent player in the biopharmaceutical sector, has announced the appointment of David Ramsay as their Interim Chief Financial Officer (CFO), effective March 23, 2026. With over three decades of experience in strategic financial leadership within the biotechnology and life sciences industries, Ramsay is expected to provide crucial oversight of the company's financial operations during their search for a permanent CFO.

Ramsay is no stranger to Halozyme. He previously served as the CFO from 2003 to 2009 and again from 2013 to 2015. His tenure saw the company transition from a private entity to a billion-dollar public biopharmaceutical powerhouse. His insights and leadership were instrumental in establishing Halozyme's foundational infrastructure during periods of substantial growth. Most recently, he served as the Senior Vice President and CFO of Bonti, Inc., until its acquisition by Allergan plc in 2018.

Dr. Helen Torley, Halozyme's President and CEO, expressed her enthusiasm regarding Ramsay's return. She stated, “I am thrilled to have the opportunity to work with David again. His deep understanding of Halozyme, combined with his exceptional capital markets expertise and long-standing record of financial leadership, makes him an invaluable partner as we advance our strategic priorities.”

The company's executive search for a permanent CFO is currently in progress, having enlisted a leading search firm to identify candidates who possess a mix of capital markets expertise and strategic insight. Ramsay will occupy the interim role until a qualified successor is appointed.

Ramsay holds a Bachelor of Science in Business Administration from the University of California, Berkeley, and an MBA in finance and strategic management from The Wharton School at the University of Pennsylvania. His educational background, paired with extensive industry experience, uniquely positions him to guide Halozyme during this pivotal time.

About Halozyme Therapeutics

Halozyme is dedicated to advancing innovative solutions aimed at improving patient experiences and outcomes for both emerging and established therapies. The company is renowned for its groundbreaking ENHANZE® drug delivery technology, utilizing the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected medications. This advancement not only alleviates treatment burdens but also enhances convenience for patients. With ENHANZE® impacting over one million lives through ten commercial products across more than 100 global markets, the technology has been embraced by leading pharmaceutical and biotechnology firms including Roche, Takeda, Pfizer, and AbbVie.

Furthermore, Halozyme is expanding its portfolio by developing partner products using the innovative Hypercon™ technology, which aims to redefine hyperconcentration of drugs and biologics, ensuring easier administration for patients in home and clinical settings. Their collaboration with Surf Bio to incorporate polymer-based systems further extends the horizons for biologic delivery.

To improve patient experience, Halozyme is also focused on developing drug-device combination products that utilize advanced auto-injector technologies. These innovations are designed to enhance reliability and tolerability, thereby promoting patient comfort and adherence to treatment.

Headquartered in San Diego, California, Halozyme also maintains offices in Ewing, NJ, Minnetonka, MN, and Boston, MA, ensuring a wide-reaching impact in the biopharmaceutical domain. For more insights into Halozyme and its offerings, visit their official website at www.halozyme.com.